HAP Trading’s Alexion Pharmaceuticals ALXN Stock Holding History

HAP Trading’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-11,087	Closed	-$996K	–	1909
2020 Q1	$996K	Buy	+11,087	New	+$1.09M	0.07%	218
2019 Q1	–	Sell	-36,263	Closed	-$3.53M	–	1458
2018 Q4	$3.53M	Buy	+36,263	New	+$4.29M	0.22%	90
2018 Q1	–	Sell	-64,135	Closed	-$7.67M	–	1253
2017 Q4	$7.67M	Buy	64,135 +50,271	+363%	+$6.12M	0.32%	67
2017 Q3	$1.95M	Sell	13,864 -96,983	-87%	-$13.2M	0.09%	173
2017 Q2	$13.5M	Sell	110,847 -9,801	-8%	-$1.14M	0.72%	38
2017 Q1	$14.6M	Buy	120,648 +102,854	+578%	+$13.3M	0.9%	21
2016 Q4	$2.18M	Buy	+17,794	New	+$2.18M	0.11%	154
2013 Q4	–	Sell	-217,153	Closed	-$25.2M	–	1393
2013 Q3	$25.2M	Buy	+217,153	New	+$23.8M	0.8%	25

Other funds holding ALXN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HAP Trading's ALXN Position: Q2 2020 in Review

HAP Trading sold out of Alexion Pharmaceuticals (ALXN) in Q2 2020, closing a stake of 11,087 shares — an estimated $996K sold.

HAP Trading first reported a position in ALXN in Q3 2013 and held it in 8 quarters. The position peaked at $25.2M in Q3 2013. 705 funds tracked by Wall St. Rank hold ALXN as of Q2 2020.

HAP Trading reported no remaining Alexion Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
HAP Trading sold 11,087 Alexion Pharmaceuticals shares in Q2 2020, an estimated $996K.
HAP Trading first reported a position in Alexion Pharmaceuticals in Q3 2013 and held it in 8 quarters.
HAP Trading's Alexion Pharmaceuticals position peaked at $25.2M in Q3 2013.
705 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2020.

Based on HAP Trading's 13F filing for Q2 2020, filed 10 Aug 2020.